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Altered sphingomyelinase and ceramide expression in the setting of
ischemic and nephrotoxic acute renal failure. Diverse physical and
chemical stimuli can activate sphingomyelinases (SMases), resulting in
sphingomyelin (SM) hydrolysis with ceramide release. Since ceramide can
profoundly impact a host of homeostatic mechanisms, the concept of a
“SM (or SMase) signaling pathway” has emerged. We recently docu-
mented that ceramide levels fall abruptly during renal ischemia, and then
rebound to twice normal values during early reperfusion (30 to 90 min).
Therefore, the present study assessed whether these ceramide changes are
paralleled, and hence potentially mediated, by comparable changes in
SMase activity. Mice were subjected to 45 minutes of renal ischemia 6 30
minutes, 90 minutes, or 24 hours of reperfusion. Renal cortices (or
isolated proximal tubules) were then assayed for SMase activity (acidic,
neutral forms). To characterize whether early post-ischemic ceramide
increments are a relatively persistent event, ceramide was assayed follow-
ing a 24-hour reperfusion period. Finally, to assess whether the observed
perturbations were unique to post-ischemic injury, SMase and ceramide
were quantified in the setting of glycerol-induced myohemoglobinuria and
anti-glomerular basement membrane (aGBM) antibody-induced acute
renal failure (ARF). Ischemia induced abrupt declines (;50%) in both
acidic and neutral SMase activities, and these persisted in an unremitting
fashion throughout 24 hours of reperfusion. Nevertheless, increased
ceramide expression (23 normal) resulted. Myohemoglobinuria also
suppressed acidic/neutral SMases, and again, “paradoxical” ceramide
increments were observed. Finally, aGBM nephritis increased ceramide
levels, but in this instance, a correlate was increased SMase activity. These
results suggest that: (1) ceramide is an acute renal “stress reactant,”
increasing in response to diverse renal insults; (2) this response may occur
independently of the classic SM pathway, since the ceramide increments
can seemingly be dissociated from increased SMase activity; and (3) given
the well documented impact of ceramide and the SM(ase) pathway on
apoptosis, cell proliferation, differentiation, and tissue inflammation, the
present results have potentially broad ranging implications for the induc-
tion and evolution of diverse forms of ARF.
Sphingomyelin (SM) has traditionally been viewed simply as a
structural component of the plasma membrane, accounting for ;5
to 15% of its total phospholipid content. However, in recent years
an expanding experimental literature, derived almost entirely
from cell culture work, indicates that SM is also an important
source of signaling molecules which can impact diverse cellular
homeostatic mechanisms. This has produced the concept that a
sphingomyelin (SM) “signaling pathway” exists [1–6]. According
to this view, a wide variety of extracellular stimuli, [such as tumor
necrosis factor a [7], interleukin 1b [8], nerve growth factor [9],
1,25 dihydroxy-vitamin D3 [10], chemotherapeutic agents (such as,
vincristine, ara C) [11, 12], and serum deprivation [13]] activate
one or more cellular sphingomyelinases (SMases), which then
hydrolyze SM, resulting in ceramide release (Fig. 1). Ceramide
then serves a “second messenger” or “biostat” [4] function,
potentially influencing a host of biological processes. These
include modulation of cell differentiation, cell cycle progression,
tissue inflammation, and induction of apoptosis [2, 5, 14, 15]. In
addition to potential direct effects, ceramide can also be meta-
bolically converted to “downstream” signaling molecules (sphin-
gosine, sphingosine-1-phosphate; Fig. 1) [16, 17]. Hence, it is clear
that SM hydrolysis/SMase activity can have potentially broad
reaching and diverse impacts on cellular homeostasis and tissue
damage.
Despite burgeoning information documenting cell ceramide
accumulation in response to a panoply of physiologic and patho-
physiologic stimuli, degrees of SMase activity during tissue injury
have received little attention. Since tissue ceramide levels presum-
ably represent the net balance of SM hydrolysis (SMase activity),
ceramide synthesis, and ceramide metabolism, it follows that
altered ceramide expression might not simply reflect changes in
SMase activity. Furthermore, it is important to note that multiple
SMases exist, they have different subcellular locations, and they
may be regulated via different stimuli [18]. The two dominant
members of this enzyme family are acidic and neutral SMases
[19]. The former accounts for ;90% of the bulk of total enzyme
activity, it has a pH optimum of ;5.0, and it resides predomi-
nantly, although not exclusively, in the lysosomal system [19, 20].
Conversely, neutral SMase (;5 to 10% of total cellular activity) is
predominantly associated with the plasma membrane, it has a pH
optimum of ;7.0, and it manifests Mg21 dependence [21]. It is
noteworthy that subcategories of both acidic and neutral SMases
exist [10, 22, 23]. Given these considerations, it is clear that
changes in ceramide expression cannot simply be taken as evi-
dence of generic “SMase activity.”
It is notable that many of the processes which ceramide can
impact have potentially important implications for the induction
and evolution of acute renal failure (such as, apoptosis, cell cycle
1 See Editorial by Shayman, p. 790.
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progression/differentiation, and proliferation). Because of this, we
recently assessed whether the expression of ceramide and its
secondary product, sphingosine, are altered during the induction
phase of ischemic acute renal failure (ARF) [24]. The results of
those studies demonstrated the following: (1) renal ischemia
induces abrupt (;50 to 70%) declines in both ceramide and
sphingosine content (consistent with decreased SMase activity);
(2) within 30 to 90 minutes of vascular reperfusion, sphingosine
and ceramide rebound to either normal (sphingosine) or twice
normal (ceramide) values (consistent with increased SMase activ-
ity); and (3) when isolated proximal tubular segments are sub-
jected to in vitro O2 deprivation injury, comparable sphingosine
and ceramide fluxes to those seen in vivo develop (suggesting that
the in vivo changes reflected, at least in part, proximal tubular cell
events). In sum, these data provided the first evidence that
alterations in the sphingomyelin “signaling pathway” develop
during the course of post-ischemic ARF.
Given these observations, the present study was undertaken to
ascertain whether altered expression of SMase, the putative
“gatekeeper” of the SM signaling pathway, is present during the
expression of ischemic-reperfusion injury. To assess whether the
postulated SMase changes are unique to this form of renal
damage, SMase activities were also quantified in two additional
and divergent models of acute renal injury: myohemoglobinuria
(glycerol injection) and nephrotoxic serum (anti-glomerular base-
ment membrane antibody)-induced ARF. To elucidate whether
SMase activity is the prime determinant of tissue ceramide
concentrations, selected renal cortical samples obtained during
the course of these studies were assayed for ceramide content.
The results of these experiments form the basis of this report.
METHODS
In vivo renal ischemia protocol
Male CD mice (25 to 35 grams; Charles River Laboratories,
Wilmington, MA, USA), maintained under standard vivarium
conditions, were used for all in vivo ischemia experiments. On the
day of experimentation, they were injected with pentobarbital (;2
mg i.p.), and after the development of deep anesthesia, they
underwent a midline abdominal incision to expose both renal
pedicles. The left kidney was subjected to 45 minutes of ischemia,
by performing renal pedicle ligation. The right kidney was left
undisturbed, serving as a non-ischemic control. During the period
of ischemia, body temperature was maintained at ;37°C. Then,
both the left (ischemic) and right (control) kidneys were resected,
iced, and the cortices dissected for subsequent SMase assay, as
described below (N 5 4 sets of control and ischemic kidneys).
In vivo ischemia/early reperfusion protocol
Nine mice were treated as noted above, except that the left
renal pedicle was occluded with a vascular clamp. After complet-
ing 45 minutes of left renal ischemia, the vascular clamp was
removed and either a 30 minutes (N 5 4) or a 90 minutes (N 5
5) vascular reperfusion period was permitted. At their comple-
tion, the post-ischemic (left) kidneys and the uninjured contralat-
eral (control) right kidneys were resected and used to assess
SMase assay, as noted below.
Spingomyelinase expression in isolated proximal tubular
segments
The following experiment was undertaken to ascertain whether
post-ischemic SMase expression, as observed in whole renal
cortex, reflected proximal tubular cell events, at least in part. To
this end, five mice were subjected to left renal pedicle occlusion 1
90 minutes of vascular reperfusion, as noted above. At its
completion, the post-ischemic kidney and the contralateral (con-
trol) kidney were resected and then proximal tubular segments
Fig. 1. Overview of metabolic conversions between sphingomyelin (SM)
and its major downstream signaling molecules (ceramide, sphingosine,
and sphingosine-1- phosphate).
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(PTS) were extracted from each by a previously described tech-
nique (cortical mincing, collagenase digestion, extensive washings,
and finally centrifugation through 31% Percoll to recover viable
PTS [25, 26]. The latter were then used to determine PTS SMase
activities by comparing the results from the control and post-
ischemic kidneys.
Sphingomyelinase and ceramide expression during late
vascular reperfusion
The following experiment was undertaken to ascertain whether
changes in SMase/ceramide expression, documented during early
ischemia/reperfusion, were merely transitory abnormalities or
whether they persisted into the late reperfusion period (potential-
ly allowing them to exert ongoing effects on renal injury and
repair). To this end, nine mice were anesthetized and subjected to
right renal resection (pedicle ligation, followed immediately by
kidney removal; providing control renal tissues). The left kidney
was subjected to renal pedicle occlusion. After completing 45
minutes of ischemia, the vascular clamp was removed, the abdo-
mens were sutured in two layers, and the mice were allowed to
recover from anesthesia. Free food and water assess were pro-
vided. Twenty-four hours post-surgery, the mice were re-anesthe-
tized and the left kidneys resected. Cortices from both the 24-hour
post-ischemic kidneys and the previously resected right (control)
kidneys were obtained, and they were used to assess either SMase
activity (4 mice) or ceramide (5 mice) concentrations, as described
below. Twenty-four hour plasma creatinines were obtained from
the post-ischemic mice to confirm the presence of functionally
significant renal damage.
Since alterations in SMase or ceramide expression in the above
24-hour post-ischemic kidneys could potentially arise as a conse-
quence of unilateral nephrectomy rather than the imposed isch-
emic damage, the independent effects of unilateral nephrectomy
on SMase and ceramide expression were assessed. To this end,
eight mice were subjected to right nephrectomy. They were then
sutured and allowed to recover from anesthesia. Twenty-four
hours post-surgery, the left kidneys were resected. Cortical sam-
ples from both the previously removed (control) kidney and the
remnant left (experimental) kidney were subjected to either
SMase (N 5 4 mice) or ceramide (N 5 4 mice) analysis.
Sphingomyelinase and ceramide expression following
myohemoglobinuric renal injury
The following experiment was undertaken to ascertain whether
altered SMase and ceramide expression are confined to post-
ischemic renal injury, or whether they more likely reflect a renal
tubular “stress response.” Towards this end, SMase and ceramide
expression in the aftermath of a nephrotoxic form of ARF
(glycerol-induced myohemoglobinuria) were assessed. Nine mice
were anesthetized with pentobarbital and then they were injected
with hypertonic glycerol (50% solution; 10 ml/kg i.m.; adminis-
tered in two equally divided doses into each upper hind limb).
Twenty-four hours post-injection, a plasma sample was obtained
for creatinine determination (to assess the severity of renal injury)
and then the kidneys were resected. Samples from five mice were
used for SMase assay; the kidneys from the remaining four mice
were used to quantitate ceramide concentrations. Kidneys from
nine normal mice, harvested concomitantly to those described
above, were used to provide normal SMase (N 5 5) and ceramide
(N 5 4) values.
Sphingomyelinase and ceramide expression in response to
acute glomerulonephritis
The following experiment was undertaken to define whether
altered SMase/ceramide expression can result from acute glomer-
ular, as well as tubular injury models of ARF. To this end, six male
Sprague-Dawley rats (Charles River; weights 444 6 70 g) were
lightly anesthetized with ether and injected via the tail vein with
sheep anti-glomerular basement membrane serum (“nephrotoxic
serum”; rats provided by W.G. Couser, M.D., University of
Washington, Seattle, WA, USA) [27]. Six weight paired rats
(439 6 77 g), injected with 1 ml/kg of non-immune sheep serum,
served as controls. Three days post-treatment (that is, the height
of injury) [27], the rats were anesthetized with pentobarbital (75
mg/kg), the abdomens were opened, a spot urine sample was
obtained by bladder aspiration, and then they were exanguinated
via the abdominal vena cava. Immediately thereafter, the kidneys
were excised and saved for either SMase or ceramide assay (1
kidney from each rat used for each assay). The terminal blood
samples were used to quantitate plasma creatinine concentrations.
The urine samples were used to semiquantitatively assess (0 to
41) urine protein concentrations (Labstix; Miles Laboratories,
Elkhart, IN, USA).
Sphingomyelinase assay
Fresh renal cortices were immediately dissected from the
resected kidneys on ice and the pieces obtained were minced,
washed twice with Hanks buffer (with Ca21/Mg21), and then
homogenized (10 strokes in a dounce homogenizer) in either an
acidic or a neutral lysis buffer for subsequent acidic or neutral
SMase assay, respectively. The acidic and neutral lysis buffers
were composed as follows: (1) acidic, 250 mM Na acetate, 1 mM
EDTA, 0.2% Triton X 100, pH 5.0; (2) neutral, 20 mM HEPES, 1
mM EDTA, 10 mM MgCl2, 2 mM Na vanadate, 0.1 mM Na2MoO4,
10 mM-b-glycerophosphate, 750 mM ATP, 10 mM PMSF, 10 mM
leupeptin, 10 mM pepstatin, 0.2% Triton X 100; pH 7.4 [28, 29].
After 20 minute incubations on ice in the appropriate lysis buffer,
the acidic and neutral preparations were pelleted (4°C) at 14,000
rpm 3 five minutes and 1000 rpm 3 five minutes, respectively [28,
29]. The supernatants were stored at 280°C until the time of
SMase assay (see below). Total protein concentrations in the
extracts were determined by the bicinchininic acid method (Pierce
Chemicals, Rockford, IL, USA).
The employed acidic SMase assay was based on the technique
of Quintern and Sandhoff [28] and performed as follows: 10
nmoles of unlabeled SM (Sigma Chemicals, St. Louis, MO, USA)
1 0.02 mCi of [N-methyl 14C]-SM (specific activity, 47 mCi/nmol;
from Amersham; Arlington Heights, IL, USA) were added to a 10
ml glass culture tube and the samples were dried under N2. Then,
50 ml of an acidic reaction buffer (250 mM Na acetate, 1 mM
EDTA, pH 5.0) and 15 mg of protein from the acidic cortical
extract were added, the volume was brought up to 100 ml in acidic
lysis buffer, and a 90 minute incubation in a 37°C shaking water
bath was completed. The reaction was then quenched and ana-
lyzed, as described below.
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Neutral SMase activity was based on the method of Chatterjee
and Ghosh [29]. Unlabeled (7 nmoles) and 0.02 mCi of [N-methyl-
14C]-SM were added to a 10 ml tube and dried, as noted above.
Fifty microliters of neutral reaction buffer (20 mM HEPES, 10 mM
MgCl2, 250 mM ATP; pH 7.4) 1 25 mg of protein from the neutral
cortical extract were added, the volume was brought to 100 ml in
neutral lysis buffer, and a two hour incubation in the 37°C shaking
water bath was completed, and then processed as noted below.
Upon completion of the acidic and neutral SMase reactions,
they were stopped by adding 0.8 ml of chloroform:methanol (2:1)
1 0.2 ml water. The samples were then vortexed and centrifuged
(2000 rpm). Samples of the upper phase (0.3 ml) were added to
scintillation vials and counted in a Beckman scintillation counter.
Acidic and neutral SMase activities were taken as nmoles 14C
labeled SM cleaved/mg protein/hr (that is, 14C-phosphocholine
release from SM) [28, 29].
Ceramide assay
Renal cortical ceramide concentrations were determined by
measuring its metabolic conversion to ceramide-1-32phosphate
under the influence of bacterial diacylglycerol (DG) kinase in the
presence of [g32P]-ATP. Since bacterial DG kinase phosphory-
lates ceramide and not just DG, the amount of ceramide-1-
phosphate formed serves as a quantitative index of ceramide
concentrations. The method of Younes et al was used [30], as
previously reported from this laboratory [24]. In brief, frozen
(280°C) cortical tissue samples were homogenized over ice in 4
volumes of phosphate buffered saline, the lipids were extracted by
the method of Bligh and Dyer, the chloroform phase was dried
under N2, and the samples were sonicated in a solubilization
buffer [24]. The samples were added to a reaction buffer contain-
ing DG kinase (Calbiochem; La Jolla, CA, USA [24] 1 a mixture
of unlabeled and labeled [g-32P] ATP (Amersham). The samples
were incubated at 22°C for 40 minutes (the resulting reaction is
linear over this period with the amount of lipid employed). The
reaction was then stopped and the lipids extracted in chloroform:
methanol:HCl in the presence of buffered saline 1 EDTA [24].
The lower organic phase was washed extensively with buffered
saline, dried under N2, and subjected to thin layer chromatogra-
phy (TLC). After visualization by autoradiography, the ceramide-
1-32P band was recovered by scraping and counted in a scintilla-
tion counter. The amount of ceramide present was calculated
from a standard curve constructed with 4 known amounts (from 0
to 12.5 mmoles) of type III ceramide (from bovine brain; Sigma
Chemicals). Values were expressed either as nmol/mg tissue dry
wt or as pmol/nmol tissue phospholipid phosphate, as determined
by the method of Van Veldhoven and Mannaerts [31].
Post-ischemic renal cortical N-acetyl-b-D-glucosaminidase
concentrations
The goal of the following experiment was to ascertain whether
post-ischemic reductions in SMase activity were simply a non
specific consequence of renal tubular injury. Towards this end,
N-acetyl-b-D-glucosaminidase (NAG) activity (which, like acidic
SMase, is a lysosomal enzyme) was assessed. Cortical tissue
extracts, obtained from those mice that had undergone either 45
minutes of ischemia 1 either 30 minutes or 24 hours of reperfu-
sion, were subjected to NAG analysis by autoanalyzer technology,
as previously performed in this laboratory [32]. The results were
expressed as milli-units of activity/mg tissue protein extract.
Calculations and statistics
All values are presented as means 6 1 SEM. Statistical compar-
isons were performed by either paired or unpaired Student’s
t-test, as appropriate, unless stated otherwise. Significance was
judged by a P value of , 0.05.
RESULTS
Ischemic/reperfusion sphingomyelinase activities
Acidic and neutral SMases contributed ;90% and ;10% of the
total SMase activity, respectively (consistent with the known
higher acidic vs. neutral enzyme activities in tissues) [19]. At the
completion of the 45-minute ischemic challenge, acidic SMase
activity had declined to approximately 50% of control tissue
values (P , 0.005; Fig. 2, far left). Ischemia also induced
significant reductions in neutral SMase activity, but to a somewhat
lesser degree (;33%; P , 0.005; Fig. 3, far left).
No rebound in either acidic or neutral SMase activity occurred
during the early (30 min; 90 min) or late (24 hr) reperfusion
Fig. 2. Renal cortical acidic SMase activity in
the aftermath of ischemic/reperfusion injury
(I/R). Abbreviations are: C, control kidneys; I,
45 minutes of renal ischemia; I/R, 45 minutes
of ischemia 1 either 30 minutes, 90 minutes, or
24 hours of reperfusion (R). At each time
point, significant depressions in acidic SMase
were observed. Nx is unilateral nephrectomy
(the results depict SMase activity in the
contralateral kidney 24 hr later). That unilateral
Nx did not independently decrease SMase
activity indicates that the observed SMase
decrements in the 24-hr post-ischemic kidneys
were due to ischemic damage, not concomitant
contralateral renal resection.
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periods, with approximate 50% depressions being consistently
observed (Figs. 2 and 3; all values P , 0.025 vs. their contralateral
controls). The depressions in acidic and neutral SMase activities
observed at 24 hours of reflow could not be ascribed to a
nonspecific impact of contralateral nephrectomy (Nx). This is
because Nx did not alter SMase activity in otherwise normal
24-hour remnant kidneys (Figs. 2 and 3; far right panels). The
plasma creatinines for the 24-hour post-ischemia/unilateral ne-
phrectomy mice were 2.3 6 0.05 mg/dl (controls 0.2 to 0.3 mg/dl),
confirming the existence of significant post-ischemic tissue dam-
age.
N-acetyl-b-D-glucosaminidase (NAG) concentrations were
comparable in the 30 minutes and 24-hour post-ischemic kidney
extracts (24 6 3 and 26 6 1 milli-units/mg protein, respectively),
compared to their contralateral 30 minute and 24 hour controls
(26 6 3; 27 6 2, respectively; NS). Thus, the reductions in SMase
activities did not appear to simply reflect nonspecific enzyme
destruction/inhibition.
Proximal tubular segment sphingomyelinase activities
As shown in Figure 4, PTS extracted from kidneys subjected to
in vivo ischemia 1 90 minutes of reperfusion manifested ;50%
depressions in acidic and neutral SMase activities (compared to
PTS harvested from nonischemic controls, P , 0.02). These
findings indicated that the post-ischemic SMase depressions ob-
served in whole renal cortex, reflected, at least in part, proximal
tubular cell events.
Sphingomyelinase expression in the aftermath of glycerol-
induced acute renal failure
Sphingomyelinase activities were variably decreased in mice
24-hours post-glycerol-induced myohemoglobinuria, compared to
values obtained in normal animals (acidic, 72 6 10 vs. 95 6 6; P 5
0.09; neutral, 4.4 6 0.9, vs. 7.3 6 0.7; P , 0.04; post-glycerol vs.
controls, respectively) (values 5 nmoles SM cleaved/mg tissue
protein/hr). There was considerable variation in the severity of
renal injury induced by glycerol injection (24-hr plasma creatinine
values ranging from 0.2 to 1.4 mg/dl post-glycerol, vs. 0.2 to 0.3
mg/dl in controls). To ascertain whether the extent of SMase
depressions corresponded with the severity of renal injury, corre-
lations between acidic and neutral SMase activities versus plasma
creatinines were sought. As demonstrated in Figure 5, striking
inverse relationships were apparent (r 5 20.93 and 20.95 for
acidic and neutral SMases, respectively; P , 0.02).
Fig. 3. Renal cortical neutral SMase activity in
the aftermath of ischemic/reperfusion injury.
Details are in the legend of Figure 1.
Fig. 4. Acidic and neutral SMase activities in
proximal tubule segments (PTS) harvested
from kidneys after 45 minutes of in vivo
ischemia (I) and 90 minutes of reperfusion (R).
Tubules harvested from non-ischemic
contralateral kidneys served as controls (C).
Significant depressions in both acidic (A) and
neutral (B) SMase were observed, indicating
that the enzyme reductions observed in whole
renal cortical tissues reflected, at least in part,
proximal tubular cell events.
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Sphingomyelinase activity in the setting of nephrotoxic serum
nephritis
In striking contrast to ischemic and myohemoglobinuric-in-
duced renal injury in which consistent depressions in SMase
activities were observed, both acidic and neutral SMase levels rose
in rats subjected to nephrotoxic serum nephritis (Fig. 6). Addi-
tional correlates of this injury model were significant rises in
plasma creatinine concentrations (aGBM rats, 0.9 6 0.2 mg/dl;
controls, 0.4 6 0.02; P , 0.05) and increased urinary protein
concentrations (aGBM rats, 3 to 41 proteinuria; controls, #21
proteinuria; P , 0.01 Wilcoxon rank sign test).
Ceramide concentrations in the aftermath of acute renal injury
Post-ischemia. Approximately 50% increments in renal cortical
ceramide concentrations were apparent by 24-hours after the
ischemic renal injury, whether the results were expressed per mg
tissue dry wt or per nmoles of tissue phospholipid phosphate (Fig.
7; P , 0.03 to , 0.002). These ceramide increments were not
simply due to the fact that these rats had a reduced renal mass
(prior unilateral nephrectomy), since unilateral nephrectomy
caused a 20% decrease in ceramide levels in an otherwise
undisturbed contralateral kidney (normal, 21 6 8 pmol/nmol
phosphate; status post-unilateral nephrectomy, 17 6 1; P 5
0.025).
Glycerol induced myohemoglobinuric renal damage. By 24-hours
post-glycerol injection, approximately 50% increments in renal
cortical ceramide concentrations were apparent, compared to
control values. These changes were statistically significant whether
expressed per tissue dry weight or per phospholipid phosphate
(Fig. 8).
Nephrotoxic serum nephritis. By three days post-aGBM serum
injection, ;35% increments in renal cortical ceramide concentra-
tions were apparent (Fig. 9).
DISCUSSION
The present study provides the first evidence to date that SMase
activity, the putative “gatekeeper” of the sphingomyelin signaling
pathway, is abruptly and markedly perturbed during the induction
and evolution of post-ischemic ARF. Based on our previous
observations that renal cortical ceramide concentrations fall by
;50 to 70% during renal artery occlusion [24], we postulated that
an acute suppression of SM hydrolysis is a correlate of acute
ischemic tissue damage. The present findings of an approximate
50% depression in renal cortical SMase activity by the completion
of a 45-minute ischemic insult supports this hypothesis. To our
knowledge, this is the first demonstration that depressions in
SMase activity result from any form of ischemic tissue damage. Of
considerable interest is that ischemia caused parallel declines in
Fig. 5. Correlation between renal cortical sphingomyelinase (SMase) activities and the extent of renal injury (plasma creatinine increments) 24 hours
following glycerol injection. Both acidic (A) and neutral (B) SMases manifested an inverse relationship with the severity of renal damage. Abbreviation
C is the control value (from normal kidneys).
Fig. 6. Sphingomyelinase (SMase) activities in
renal cortex three days following the induction
of nephrotoxic serum (aGBM-mediated)
nephritis (the purported height of this injury
model). Significant increments in activity of
each enzyme were apparent, compared to
values obtained in weight/age matched controls.
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acidic and neutral SMase activities. This is noteworthy from at
least two perspectives: first, although differing “effector mech-
anisms” may control individual SMases [18], the present data
clearly show that during major cellular insults, at least some
shared determinants of their expression exist; and second, given
that acidic and neutral SMases have markedly different intra-
cellular locations (such as, lysosomal and plasma membranes,
respectively), reductions in both enzymes indicate biological
consequences at multiple subcellular sites. It is likely that
these reductions in SMase activity contribute to previously
documented ischemia-triggered ceramide depressions [24].
However, enzyme loss by itself is not sufficient to produce this
result. This is because even complete SMase inhibition would
require concomitant ceramide consumption to effect a cer-
amide deficient state. Unfortunately, ceramide’s metabolic
fate during ischemia (that is, whether it is converted back to
Fig. 7. Renal cortical ceramide levels following
45 minutes of ischemia (I) 1 24 hours of
reperfusion (I/R). Significant increments were
observed, whether the results were expressed
per tissue dry wt (A) or per tissue phospholipid
phosphate (B).
Fig. 8. Renal cortical ceramide concentrations
24 hours following induction of
myohemoglobinuric acute renal failure (by
glycerol injection). There was an approximate
33 to 50% increase in ceramide values, whether
expressed per tissue dry wt (A) or per
phospholipid phosphate (B).
Fig. 9. Renal cortical ceramide concentrations
in the setting of nephrotoxic serum (anti-
glomerular basement membrane, aGBM)
nephritis. Approximately 33 to 50% ceramide
increments were observed, whether expressed
per tissue dry wt (A) or per phospholipid
phosphate (B).
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SM/glycosphingolipids, or degraded to downstream products)
remains unknown.
Our previous observations that ceramide levels rebound to
supranormal (;23) levels within 30 minutes of vascular reflow
[24] suggested to us that SMase activation could be a correlate of
the early reperfusion period. By analogy, such a result would be
reminiscent of enhanced PLA2 activity during post-ischemic renal
injury in at least two respects: (1) enhanced activity of each
enzyme family would be expected to contribute to tissue injury via
degradation of structural membrane constituents (sphingomyelin
and glycero-phospholipids, respectively) [33]; and (2) byproducts
of these reactions would generate potent cell signaling molecules
(ceramide and arachidonic acid, respectively). Although we now
demonstrate that increased ceramide expression is not merely a
transient reperfusion event, (that is, it has now been documented
after 24 hours post-reperfusion), it is apparent that this result
cannot simply be explained by increased SMase activity. This is
because at each time point (0, 30 min, 90 min, and 24 hr of
reflow), stable reductions in both acidic and neutral SMases were
observed. Thus, it seems likely that increased ceramide synthesis
and/or decreased ceramide catabolism, rather than accelerated
SM hydrolysis, are the principal reason(s) for the observed
post-ischemic ceramide increments. Consistent with this hypoth-
esis is that reduced SM content is not a feature of post-ischemic
renal damage [24, 33].
The cause of the persistent depressions in post-ischemic SMase
activities remains unknown. However, we speculate that enzyme
destruction during ischemia (such as, due to proteolysis), coupled
with a failure of resynthesis during reperfusion is most likely
involved. This is because a physiologically regulated suppression
of enzyme activity would be unlikely to cause such prolonged and
stable decrements. Of note is that acute tubular injury ushers in a
generalized state of protein synthesis inhibition [34–36] (except-
ing “stress activated” or heat shock proteins). Thus, were initial
proteolytic enzyme destruction to occur, enzyme depletion would
persist until new protein synthesis could occur. A crucial piece of
information needed to support the above hypothesis would be
demonstration of enzyme loss, as assessed by Western blot
analysis. However, the lack of commercially available SMase
antibodies has, to date, precluded this analysis. Finally, it is
noteworthy that the proposed SMase destruction does not appear
to be a completely nonspecific event, or simply an extraction
artifact conditioned by prior in vivo renal damage. This is based on
the fact that lysosomal NAG activity was well preserved at both 30
minutes and 24 hours of vascular reperfusion, times at which the
activity of lysosomal (acidic) SMase activity was markedly de-
pressed.
To ascertain whether the above documented changes are
unique to ischemic-reperfusion injury, or whether they might
reflect a more generalized renal “stress” response, SMase and
ceramide expression were measured during the maintenance
phase of glycerol-induced myohemoglobinuric ARF. Of note is
that the mechanisms initiating myohemoglobinuric and ischemic
tubular injury dramatically differ (iron-driven oxidant stress and
ATP depletion, respectively) [37, 38]. Thus, were comparable
SMase and ceramide changes to occur in each of these injury
models, a generalized biological phenomenon would be sug-
gested. Indeed, this appears to be the case since essentially
identical ceramide increments and SMase decrements were ob-
served in the aftermath of glycerol- and ischemia-induced renal
damage. The striking inverse relationship between the extent of
renal injury in the glycerol model (plasma creatinine) and the
observed SMase depressions (r 5 20.93 to 20.95) supports the
concept that the SMase losses were a consequence of acute
tubular damage. That we were able to document SMase depres-
sions in proximal tubules isolated from post-ischemic kidneys
(Fig. 4), and that we have previously noted ceramide increments
in post-hypoxic tubules [24] underscore that our whole cortical
results reflect, at least in part, proximal tubular events. Finally,
that the post-glycerol ceramide increments were expressed in the
setting of decreased SMase activity once again suggests that de
novo ceramide synthesis, rather than SM hydrolysis, is a more
likely determinant of ceramide expression in the aftermath of
acute tubular damage. That at least one form of cell injury
(daunorubicin) has been shown to up-regulate ceramide produc-
tion via increasing ceramide synthase levels, provides experimen-
tal support for this possibility [39].
The final goal of this study was to ascertain whether major
perturbations in SMase and ceramide expression are uniquely
confined to models of acute tubular injury, or whether they may
also develop during other pathophysiologic forms of ARF. To
address this issue, SMase and ceramide concentrations were
determined three days following the induction of aGBM-medi-
ated acute glomerulonephritis. Once again, significant ceramide
increments were observed. If these findings are interpreted in the
context of the post-ischemic and post-glycerol results, the concept
of ceramide as an acute renal “stress reactant” begins to emerge.
It is tempting to postulate that in the case of nephrotoxic serum
nephritis, increased SM hydrolysis contributed to the ceramide
increments, since both acidic and neutral SMase activation were
observed. However, that ceramide elevations can develop even in
the setting of acute SMase depletion (such as, as evidenced by the
post-ischemia and post-glycerol results) makes this a highly spec-
ulative conclusion. Why glomerular injury activates, whereas
tubular injury inactivates, renal cortical SMases remains un-
known. This may simply reflect the fact that highly divergent
injury models, triggering different mediators of tissue injury (such
as, cytokine release, ATP depletion, oxidative stress) affecting
differing cell types (for example, glomeruli or tubules) and to
varying degrees elicit different effects on a given enzyme activity.
Indeed, the localization of the SMase and ceramide increments
following aGBM-induced renal injury (that is, are they glomerular
and/or tubular in origin?) remains to be defined.
The overall pathophysiologic impact of enhanced ceramide
expression on the evolution of in vivo acute renal injury is an
exceedingly difficult issue to dissect. This is because ceramide and
its downstream products (sphingosine, sphingosine-1-phosphate)
can each impact multiple biological processes. Nevertheless,
based on available cell culture information, at least three note-
worthy areas for speculation exist. First, since ceramide can
initiate apoptosis, an attractive hypothesis is that the observed
ceramide increments help mediate this process in the setting of
toxic or ischemic ARF. Noteworthy in this respect are that tubular
and glomerular cell apoptosis have been implicated as important
pathogenic events in the induction and recovery phases of diverse
forms of acute renal damage [40–43]. Second, it has been
previously documented that ceramide, arachidonic acid, and
phospholipase A2 (PLA2), each of which are major signaling
molecules, exert interactive or counter-regulatory effects [44–46].
For example, we have demonstrated that ceramide can enhance
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PLA2-mediated tubular cell detachment, while at the same time
markedly attenuating arachidonic acid’s potent cytotoxic effects
[24]. Since PLA2 activation and arachidonic generation are com-
mon events in acute ischemic and toxic tubular damage [33, 38], a
corresponding ceramide increment could modulate the expression
of this injury pathway. Third, increased ceramide expression could
help render tubular cells relatively resistant to subsequent, super-
imposed attack. It has long been recognized that within 24 hours
of acute tubular or glomerular damage (for example, ischemia,
myoglobinuria [47, 48]; nephrotoxic serum nephritis [49, 50]),
renal tubular cells acquire a “cytoresistant” state. This serves to
prevent or mitigate recurrent episodes of ARF. We previously
speculated that altered sphingolipid expression within tubular
cells might contribute to this result. This was based on the fact
that incubating cultured tubular cells with sphingosine (which is
then converted to ceramide) induces this cytoresistant state [51].
The present results documenting increased renal cortical cer-
amide accumulation in three disparate renal injury models (isch-
emia, myohemoglobinuria, nephrotoxic serum nephritis), each of
which confers cytoresistance, provides important, albeit indirect,
support for this hypothesis. That ceramide can depress known
pathways of acute tubular injury (oxidant stress, cell Ca21 influx)
[52], and that altered ceramide expression can induce cytoresis-
tance against TNFa- and radiation-induced injury [53, 54] lends
further credence to this possibility.
Given each of these considerations, it appears likely that the
presently documented ceramide increments (that is, a ceramide
“stress response”) could have a broad range of effects on the
evolution of acute renal injury and secondary adaptations to it.
Less certain is whether the corresponding alterations in SMase
activity are also important. Clearly, in the case of acute tubular
injury, a loss of SMase activity could attenuate the function of a
normally regulated SM signaling pathway. Indeed, that ceramide,
the second messenger of this pathway, may be elevated indepen-
dent of it, could also render the SM(ase) pathway functionally
incompetent. Clearly, these remain highly conjectural issues at
this time. What does seem clear, however, is that “increased
ceramide expression” and “increased SMase activity” are not
necessarily linked (such as in the case of ischemic or myohemo-
globinuric ARF). This adds a new level of complexity to the study
of the sphingomyelin signaling pathway.
ACKNOWLEDGMENTS
The authors thank William G. Couser, M.D., for providing rats with
nephrotoxic serum nephritis. This work was supported by grants from the
National Institutes of Health (DK 38432), the Northwest Kidney Foun-
dation (Seattle, WA, USA), Seikagaku Pharmaceutics (Tokyo, Japan),
and Abbott Laboratories (Abbott Park, IL, USA).
Reprint requests to Richard A. Zager, M.D., Fred Hutchinson Cancer




Abbreviations used in this article are: ARF, acute renal failure; aGBM,
anti-glomerular basement membrane; ATP, adenosine triphosphate; DG,
diacylglycerol; NAG, N-acetyl-B-D-glucosaminidase; Nx, nephrectomy;
PLA2, phospholipase A2; PTS, proximal tubule segments; SM, sphingo-
myelin; SMase, sphingomyelinase; TLC, thin layer chromatography;
TNFa, tumor necrosis factor alpha.
REFERENCES
1. ZHANG Y, KOLESNICK R: Signaling through the sphingomyelin path-
way. Endocrinology 136:4157–4160, 1995
2. HANNUN Y: The sphingomyelin cycle and second messenger function
of ceramide. J Biol Chem 269:3125–3128, 1994
3. TESTI R: Sphingomyelin breakdown and cell fate. Trend Biochem Sci
21:468–471, 1996
4. HANNUN YA: Functions of ceramide in coordinating cellular re-
sponses to stress. Science 274:1855–1859, 1996
5. OBEID LM, HANNUN YA: Ceramide: A stress signal and mediator of
growth suppression and apoptosis. J Cell Biochem 58:191–198, 1995
6. MATHIAS S, KOLESNICK R: Ceramide: A novel second messenger. Adv
Lipid Res 25:65–90, 1993
7. KIM MY, LINARDIC C, OBEID L, HANNUN YA: Identification of
sphingomyelin turnover as an effector mechanism for the action of
tumor necrosis factor alpha and gamma-interferon. Specific role in
cell differentiation. J Biol Chem 266:484–489, 1991
8. BALLOU LR, CHAO CP, HOLNESS MA, BARKER SC, RAGHOW R:
Interleukin-1-mediated PGE2 production and sphingomyelin metab-
olism. Evidence for the regulation of cyclooxygenase gene expression
by sphingosine and ceramide. J Biol Chem 267:20044–20050, 1992
9. DOBROWSKY RT, WERNER MH, CASTELLINO AM, CHAO MV, HANUN
YA: Activation of the sphingomyelin cycle through the low-affinity
neurotrophin receptor. Science 265:1596–1599, 1994
10. OKAZAKI T, BIELAWSKA A, BELL RM, HANNUN YA: Role of ceramide
as a lipid mediator of 1 alpha, 25-dihydroxyvitamin D3-induced HL-60
cell differentiation. J Biol Chem 265:15823–15831, 1990
11. STRUM JC, SMALL G, PAUIG SB, DANIEL LW: 1-Beta-D arabino-
furanosylcytosine stimulates ceramide and diglyceride formation in
HL-60 cells. J Biol Chem 269:15493–15497, 1994
12. ZHANG J, ALTER N, REED JC, BORNER C, OBEID LM, HANNUN YA:
Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc
Natl Acad Sci USA 93:5325–5328, 1996
13. JAYADEV S, LIU B, BIELAWSKA AE, LEE JY, NAZAIRE R, PUSHKAREVA
M, OBEID LM, HANNUN YA: Role of ceramide in cell cycle arrest.
J Biol Chem 270:2047–2052, 1994
14. SPIEGEL S, MERRILL AH JR: Sphingolipid metabolism and cell growth
regulation. FASEB 10:1388–1397, 1996
15. SABA JD, OBEID LM, HANNUN YA: Ceramide: An intracellular
mediator of apoptosis and growth suppression. Philosphical Trans
Royal Soc London-Series B: Biol Sci 351:233–240, 1996
16. SPIEGEL S, MILSTEIN S: Sphingolipid metabolites: Members of a new
class of lipid second messengers. J Membr Biol 146:225–237, 1995
17. BUEHER BM, BELL RM: Sphingosine kinase: Properties and cellular
functions. Adv Lipid Res 26:59–67, 1993
18. LIU B, HANNUN YA: Inhibition of the neutral magnesium-dependent
sphingomyelinase by glutathione. J Biol Chem 272:16281–16287, 1997
19. SPENCE MW: Sphingomyelinases. Adv Lipid Res 26:3–23, 1993
20. QUINTERN LE, WEITZ G, NEHRKORN H, TAGER JM, SCHRAM AW,
SANDHOFF K: Acid sphingomyelinase from human urine: Purification
and characterization. Biochim Biophys Acta 922:323–326, 1987
21. CHATTERJEE S: Neutral sphingomyelinase. Adv Lipid Res 26:25–48,
1993
22. OKAZAKI T, BIELAWSKA A, DOMAE N, BELL RM, HANNUN YA:
Characteristics and partial purification of a novel cytosolic, magne-
sium-independent, neutral sphingomyelinase activated in the early
signal transduction of 1 alpha, 25 dihydroxyvitamin D3-induced HL-60
cell differentiation. J Biol Chem 269:4070–4077, 1994
23. SPENCE MW, BYERS DM, PALMER FB, COOK HW: A new Zn21
stimulated sphingomyelinase in fetal bovine brain. J Biol Chem
264:5358–5363, 1989
24. ZAGER RA, IWATA M, CONRAD DS, BURKHART KM, IGARASHI Y:
Altered ceramide and sphingosine expression during the induction
phase of ischemic acute renal failure. Kidney Int 52:60–70, 1997
25. ZAGER RA: Mitochondrial free radical production induces lipid
peroxidation during myohemoglobinuria. Kidney Int 49:741–751, 1996
26. ZAGER RA, BURKHART KM, CONRAD DS, GMUR DJ, IWATA M:
Phospholipase A2-induced cytoprotection of proximal tubules: Poten-
tial determinants and specificity for ATP depletion-mediated injury.
J Am Soc Nephrol 7:64–72, 1996
27. COUSER WG, SALANT DJ, STILMANT MM, ARBEIT LA, DARBY C,
SLIOGERIS VG: The effects of aminonucleoside of puromycin and
Zager et al: Sphingomyelin and ceramide in ischemia and ARF 581
nephrotoxic serum on subepithelial immune deposit formation in
passive Heymann nephritis. J Lab Clin Med 94:917–932, 1979
28. QUINTERN LE, SANDHOFF K: Human acid sphingomyelinase from
human urine. Methods Enzymol 197:536–540, 1991
29. CHATTERJEE S, GHOSH N: Purification of neutral sphingomyelinase
from human urine. Methods Enzymol 197:540–547, 1991
30. YOUNES A, KAHN DW, BESTERMAN WR, BITTMAN R, BYUN H-S,
KOLESNICK RN: Ceramide is a competitive inhibitor of diacylglycer-
okinase in vitro and in intact human leukemia (HL-60) cells. J Biol
Chem 267:842–847, 1992
31. VAN VELDHOVEN PP, MANNAERTS GP: Inorganic and organic phos-
phate measurements in the nanomolar range. Anal Biochem 161:45–
48, 1987
32. FINK J, COOPER M, BURKHART K, ZAGER RA: Marked enzymuria
following bone marrow transplantation: A correlate of veno-occlusive
disease-induced “hepatorenal syndrome.” J Am Soc Nephrol 6:1655–
1660, 1995
33. MATTHYS E, PATEL Y, KREISBERG J, STEWART JH, VENKATACHALAM
MA: Lipid alterations induced by renal ischemia: Pathogenic factor in
membrane damage. Kidney Int 26:153–161, 1984
34. GOERING PL, FISHER BR, CHAUDHARY PP, DICK CA: Relationship
beteen stress protein induction in rat kidney by mercuric chloride
nephrotoxicity. Toxicol Appl Pharmacol 113:184–191, 1992
35. WILKS MF, KWIZERA EN, BACH PH: Assessment of heavy metal
toxicity in vitro using isolated rat glomeruli and proximal tubular
fragments. Renal Physiol Biochem 13:275–284, 1990
36. IWATA M, ZAGER RA: Myoglobin induces transient growth arrest in
cultured human proximal tubular cells. Kidney Int 50:796–804, 1996
37. ZAGER RA: Rhabdomyolysis and myohemoglobinuric acute renal
failure. (Perspectives in Clinical Nephrology) Kidney Int 49:314–326,
1996
38. WEINBERG JM: The cell biology of ischemic renal injury. (Editorial
Review) Kidney Int 39:476–500, 1991
39. BOSE R, VERHEIJ M, HAIMOVITZ-FRIEDMAN A, SCOTTO K, FUKS Z,
KOLESNICK R: Ceramide synthase mediates daunorubicin-induced
apoptosis: An alternative mechanism for generating death signals. Cell
82:405–414, 1995
40. ZAGER RA, FUERSTENBERG SM, BAEHR PH, MYERSON D, TOROK-
STORB B: An evaluation of antioxidant effects on recovery from
postischemic acute renal failure. J Am Soc Nephrol 4:1588–1597, 1994
41. BERRI R, SYMON Z, BREZIS M, BEN-SASSON SA, BAEHR PH, ROSEN S,
ZAGER RA: Rapid DNA fragmentation from hypoxia along the thick
ascending limb of rat kidneys. Kidney Int 47:1806–1810, 1995
42. SHAH SV: Apoptosis. J Lab Clin Med 124:169–177, 1994
43. LIEBERTHAL W, LEVINE JS: Mechanisms of apoptosis and its potential
role in renal tubular cell injury. Am J Physiol 271:F477–F488, 1996
44. HAYAKAWA M, JAYADEV S, TSUJIMOTO M, HANNUN YA, ITO F: Role
of ceramide in stimulation of the transcription of cytosolic phospho-
lipase A2 and cyclo-oxygenase 2. Biochem Biophys Res Commun
220:681–686, 1996
45. BRINDLEY DN, ABOUSALHAM A, KIKUCHI Y, WANG CN, WAGGONER
DW: “Cross talk” between the bioactive glycerolipids and sphingolip-
ids in signal transduction. Biochem Cell Biol 74:469–476, 1996
46. HUANG HW, GOLDBERG EM, ZIDOVETZKI R: Ceramide induces
structural defects into the phosphatidylcholine bilayers and activates
phospholipase A2. Biochem Biophys Res Commun 220:834–838, 1996
47. HONDA N, HISHIDA A, IKUMA K, YONEMURA K: Acquired resistance
to acute renal failure. Kidney Int 31:1233–1238, 1987
48. ZAGER RA, IWATA M, BURKHART K, SCHIMPF BA: Post-ischemic
acute renal failure protects proximal tubular cells from O2 deprivation
injury, possibly by inducing uremia. Kidney Int 45:1760–1768, 1994
49. ZAGER RA, BALTES LA: Progressive renal insufficiency induces
increasing protection against ischemic acute renal failure. J Lab Clin
Med 103:511–523, 1984
50. VOGT BA, SHANLEY TP, CROATT A, ALAM J, JOHNSON KJ, NATH KA:
Glomerular inflammation induces resistance to tubular injury in the
rat. A novel form of acquired, heme oxygenase-dependent resistance
to renal injury. J Clin Invest 98:2139–2145, 1996
51. IWATA M, HERRINGTON J, ZAGER RA: Sphingosine: A mediator of
acute renal tubular injury and subsequent cytoresistance. Proc Nat
Acad Sci USA 92:8970–8974, 1995
52. WONG K, LI XB, HUNCHUK N: N-acetylsphingosine (C2-ceramide)
inhibited neutrophil superoxide formation and calcium influx. J Biol
Chem 270:3056–3062, 1995
53. CAI Z, BETTAIEB A, MAHDANI NE, LEGRIS LG, STANCOU R, MASLIAH
J, CHOUAIB S: Alteration of the sphingomyelin/ceramide pathway is
associated with resistance of human breast carcinoma MCF7 cells to
tumor necrosis factor-alpha-mediated cytotoxicity. J Biol Chem 272:
6918–6926, 1997
54. CHMURA SJ, NODZENSKI E, BECKETT MA, KUFE DW, QUINTANS J,
WEICHSELBAUM RR: Loss of ceramide production confers resistance
to radiation-induced apoptosis. Cancer Res 57:1270–1275, 1997
Zager et al: Sphingomyelin and ceramide in ischemia and ARF582
